← All trials
NCT04540692
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 23, 2020
- Primary completion
- Nov 1, 2020
- Completion date
- Sep 23, 2028
- First posted
- Sep 7, 2020
- Last posted
- Sep 7, 2020
- Enrollment
- 494
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Latin American Cooperative Oncology GroupLead sponsor
- Latin American Cooperative Oncology GroupStudy chair
- Government of BrazilOverall official - principal investigator
- Brazilian Breast Cancer Study Group (GBECAM)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.